NCT03693534

Brief Summary

A prospective study of the evaluation of the clinical IVF (in vitro fertilization) results after following Long Antagonist protocol for Controlled Ovarian Stimulation (COS) versus following Long Agonist protocol

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 15, 2017

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

September 24, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 3, 2018

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2021

Completed
Last Updated

October 8, 2020

Status Verified

October 1, 2020

Enrollment Period

4.4 years

First QC Date

September 24, 2018

Last Update Submit

October 6, 2020

Conditions

Keywords

Long AntagonistLong agonistclinical pregnancy ratelive birth rateovarian stimulationIVF

Outcome Measures

Primary Outcomes (2)

  • Clinical Pregnancy Rate according to stimulation protocol

    Clinical Pregnancy Rate according to stimulation protocol

    6 weeks to 42 weeks after embryo transfer

  • Number of formed blastocysts in each group of patients

    The number of the formed blastocysts in each group of patients according to the COS protocol

    5 days after the OPU day

Secondary Outcomes (1)

  • Live Birth Rate according to stimulation protocol

    6 weeks to 42 weeks after embryo transfer

Study Arms (2)

Long Antagonist Protocol

Clinical Pregnancy Rate, Live Birth Rate and Blastulation Rate of patients who followed Long Antagonist Protocol for Controlled Ovarian Stimulation.

Diagnostic Test: Clinical Pregnancy Rate

Long Agonist Protocol

Clinical Pregnancy Rate and Live Birth Rates and Blastulation Rate of patients who followed Long Agonist Protocol for Controlled Ovarian Stimulation.

Diagnostic Test: Clinical Pregnancy Rate

Interventions

The Clinical Pregnancy, Live Birth Rate and Blastulation Rate according to the protocol of COS

Long Agonist ProtocolLong Antagonist Protocol

Eligibility Criteria

Age18 Years - 39 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Women 18- 39 years old who follow COS with the Long Antagonist Protocol or with Long Agonist Protocol

You may qualify if:

  • primary infertility
  • age 18-39 years; body mass index (BMI) 18-29kg/m2;
  • regular menstrual cycle of 26-35days,
  • presumed to be ovulatory;
  • early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

You may not qualify if:

  • women with diabetes and other metabolic disease
  • women with heart disease, QT prolongation,heart failure
  • elevated liver enzymes, liver failure, hepatitis
  • women with inflammatory or autoimmune disease
  • abnormal karyotype;
  • polycystic ovarian syndrome,
  • endometriosis stage III/IV;
  • history of being a 'poor responder',
  • defined as \>20 days of gonadotrophin in a previous stimulation cycle, or any previous cancellation of a stimulation cycle due to limited follicular response, or development of less than 4 follicles 15 mm in a previous stimulation cycle; history of recurrent miscarriage; severe OHSS in a previous stimula- tion cycle or any contraindication for the use of gonadotrophins.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assisting Nature

Thessaloniki, 57001, Greece

RECRUITING

MeSH Terms

Conditions

Pregnancy, Ovarian

Condition Hierarchy (Ancestors)

Pregnancy, EctopicPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Evaggelos Papanikolaou, MD, PhD

    Assisting Nature

    PRINCIPAL INVESTIGATOR
  • Robert Najdecki, MD, PhD

    Assisting Nature

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Evaggelos Papanikolaou, MD,PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Papanikolaou Evaggelos, MD, PhD, Fertility Specialist, Scientific Director at Assisting Nature IVF Clinic

Study Record Dates

First Submitted

September 24, 2018

First Posted

October 3, 2018

Study Start

February 15, 2017

Primary Completion

June 30, 2021

Study Completion

June 30, 2021

Last Updated

October 8, 2020

Record last verified: 2020-10

Locations